Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7158007 | 0.88 | SGMS2 (0.53) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL14003834 | 0.87 | SGMS2 (0.55) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL6988248 | 0.85 | NPC1 (0.60) | NPC1KMT2ALMNAL3MBTL1ALDH1A1 | |
| SCHEMBL6988245 | 0.85 | NPC1 (0.60) | NPC1KMT2ALMNAL3MBTL1ALDH1A1 | |
| SCHEMBL4879716 | 0.83 | SGMS2 (0.56) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL7531833 | 0.80 | SGMS2 (0.58) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL9643397 | 0.78 | SGMS2 (0.60) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL6243854 | 0.78 | NPC1 (0.64) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL7160628 | 0.78 | PTPN1 (0.53) | NPC1GAAMEN1KMT2AMAPT | |
| SCHEMBL9642440 | 0.78 | SGMS2 (0.59) | SGMS2NPC1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370510-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6548546-B2 | Administering a 2-hydroxy-4-oxo- or 4,6-dioxo-6-pheny-l or naphthyl- hex-2-enoic acid; viricides; AIDS/ARC | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20020123527-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-05 | — | — | US | disclosed |
| WO-2001098248-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123527-A1 | HIV integrase inhibitors | POLM, NPC1, AP1M1 | SGMS2 2208/4885NPC1 2/4885GAA 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.